ICU Earnings Forecast
Looking ahead, ICU remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q4 project quarter revenue of 245.00K and an EPS of -0.11.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been No Change by 0%, while EPS estimates have been No Change by 0%. For the upcoming Q4 2025, revenue estimates have been adjusted No Change by 0% . These revisions correlate with a -60.46% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in ICU long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
1Y
3Y
5Y
Currency: USD
--
Revenue Estimate-:0
--
EPS Estimate-:0
—
Stock Price0
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Unlock the reason behind revisions!
Revenue Estimates for Q4 2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Down
-60.46%
In Past 3 Month
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Al Analysis
Earnings Surprise Analysis
Revenue
EPS
1Y
3Y
Al Analysis
Earnings Reaction
The chart below shows how ICU performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ICU sees a +8.10% change in stock price 10 days leading up to the earnings, and a -16.15% change 10 days following the report. On the earnings day itself, the stock moves by -2.42%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed -17.39% on the day following the earnings release and then changed by -31.19% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
People Also Watch
Frequently Asked Questions
What were the key highlights of ICU's latest earnings report for FY2025Q3?
ICU reported its FY2025Q3 earnings on 2025-11-13, showcasing a revenue of 183.00K against an estimate of 250.00K, resulting in a -26.8% surprise. The EPS was -0.13, surpassing the expected -0.15 by 13.33% . The stock experienced a -17.39% price change on the earnings day and a -32.36% change over the next five days, reflecting market reactions to the results.
How did ICU's stock price react after the FY2025Q3 earnings release?
Following ICU's FY2025Q3 earnings announcement on 2025-11-13, the stock price moved by -17.39% on the day of the release. Over the subsequent five days, it saw a -32.36% change. Historically, ICU's stock price tends to shift by an average of +8.10% in the 10 days leading up to earnings and -16.15% in the 10 days following, providing insight into potential market.
What are the revenue and EPS estimates for ICU for 2025/Q4?
For 2025/Q4, analysts estimate ICU’s annual revenue to reach 245.00K, while the EPS is projected at -0.11. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates No Change by 0% over the past three months, indicating analyst expectation in the company’s performance.
How does ICU's stock price correlate with earnings forecast revisions?
The correlation between ICU's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved No Change by 0% . This trend suggests that price dips could present buying opportunities for investors.
What should investors expect from ICU's next earnings report?
Based on historical trends, ICU's stock price typically moves by +8.10% in the 10 days before its earnings and -16.15% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.11 and revenue of 245.00K.
What is the sentiment in SeaStar Medical Holding Corp (ICU) Q1 2025 Earnings Call Summary?
The earnings call highlights a fourfold revenue increase and a significant reduction in net loss, suggesting improved financial performance. The company is expanding its market presence with QUELIMMUNE and has a substantial market opportunity in adult AKI. Despite some regulatory and competitive risks, the management's optimistic outlook on faster approvals and pipeline growth is encouraging. The Q&A session revealed active engagement in clinical trials and expansion in pediatric sites, supporting a positive sentiment. Overall, the financial improvements and strategic positioning point to a potential 2% to 8% stock price increase.